Are GLP-1s Linked to Optic Neuropathy?
A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.
By
Andrea Surnit
July 14, 2026
Clinical Scorecard: Are GLP-1s Linked to Optic Neuropathy?
At a Glance
Category Detail
Condition Anterior Ischemic Optic Neuropathy Key Mechanisms Association with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors. Target Population Patients with type 2 diabetes Care Setting Nationwide, register-based cohort study
Key Highlights
GLP-1 receptor agonists associated with a higher risk of anterior ischemic optic neuropathy compared to SGLT-2 inhibitors. Absolute risks at 1 year were 0.04% for GLP-1 and 0.02% for SGLT-2. At 5 years, risks were 0.12% for GLP-1 and 0.07% for SGLT-2. Differences in risk were reduced in patients receiving metformin. Residual confounding cannot be excluded. Guideline-Based Recommendations
Diagnosis
Anterior ischemic optic neuropathy identified through national patient register. Management
Consider diabetes severity and metformin use when evaluating risks. Monitoring & Follow-up
Monitor for signs of anterior ischemic optic neuropathy in patients using GLP-1 receptor agonists. Risks
Low absolute risks of anterior ischemic optic neuropathy in patients using GLP-1 receptor agonists. Patient & Prescribing Data
Patients with type 2 diabetes initiating GLP-1 receptor agonists or SGLT-2 inhibitors.
Cautious interpretation of risk increase among GLP-1 users due to low absolute event rates.
Clinical Best Practices
Assess individual patient risk factors when prescribing GLP-1 receptor agonists. Utilize propensity score weighting to balance demographic and clinical characteristics. Related Resources & Content
